If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The share price of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY ) was buoyant in early trading today after the company released its Q4 and full-year 2024 earnings. At the time o ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Justin Chakma - Chief Business Offi ...

This quarterly report represents an earnings surprise of 1,400%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.20, delivering a surprise of -11.11%. ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. Empirical research shows a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 (State or other jurisdicti ...

Financial Performance - Preliminary nef y® net product revenue for Q4 2024 was approximately $6.5 million, with total net product sales for 2024 of approximately $7.1 million since launch[5]. - Cash, cash equivalents, and short-term investments were approximately $314.0 million as of December 31, 2024, expected to support operations for at least three years[5]. - The company aims to achieve a long-term total gross-to-net revenue target of 50% through consistent contracting[9]. Product Delivery and Usage - Over 14,500 nef y two-pack units were delivered in Q4 2024, including more than 1,500 units in the last week of the year[5]. - More than 3,000 healthcare providers have prescribed nef y to date, with 80% in the highest decile for prescribing epinephrine[5]. - More than 1,750 healthcare providers have participated in the nef y Experience Program to date[5]. Market Strategy and Coverage - The company is on track for over 60% commercial insurance coverage by the end of Q1 2025 and over 80% by the end of Q3 2025[9]. - A branded direct-to-consumer marketing campaign for nef y is set to launch in May 2025, aimed at increasing brand recognition[9]. Regulatory and Conference Participation - The sNDA for nef y 1 mg for children weighing 15 to 30 kg has a PDUFA target action date of March 6, 2025, with expected product availability in Q2 2025[9]. - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025[1].

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commer ...

neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the U.S. Food and Drug Administration (FDA) has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic React ...

neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the U.S. Food and Drug Administration (FDA) has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic Reacti ...

Core Points - ARS Pharmaceuticals, Inc. will host a conference call on March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights [1] - The company is dedicated to empowering at-risk patients and caregivers to protect against allergic reactions that could lead to anaphylaxis [3] Company Information - ARS Pharmaceuticals is commercializing neffy® 2 mg (trade name EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [3] - The product is indicated for emergency treatment of allergic reactions due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis in both adults and children [3] Upcoming Events - ARS Pharma Management will participate in several investor conferences, including a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2025, and investor meetings at the 37th Annual Roth Conference from March 16-18, 2025 [4]

Core Insights - ARS Pharmaceuticals has expanded access to neffy, an epinephrine nasal spray, to approximately half of all patients managing Type 1 allergic reactions by adding it to 30 formularies, including those of Cigna Healthcare, Navitus Health Systems, and OptumRx [1][2][3] Group 1: Product Information - Neffy is the first FDA-approved epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, for patients weighing 30 kg or more [4][7] - The product is designed for rapid administration, is portable, and has a shelf-life of 30 months with temperature stability up to 122 degrees Fahrenheit [4] - A supplemental NDA for neffy 1 mg, aimed at children over four years old weighing 15 to 30 kg, has a target action date of March 6, 2025, with expected availability by the end of May 2025 [5] Group 2: Market Impact - The addition of neffy to formularies improves coverage for approximately 20 million individuals diagnosed with severe Type I allergic reactions who require epinephrine therapy [3][15] - Millions of patients now have improved access to neffy through commercial insurance, with a low copay of $25 available for those insured by OptumRx, Cigna Healthcare, and Navitus Health Systems [2][3] Group 3: Company Commitment - ARS Pharmaceuticals is committed to ensuring continued access to neffy for patients and caregivers, highlighting the critical demand for a nasal spray option in the severe allergy community [2][3] - The company is actively working with UnitedHealthcare to add neffy to their formulary [2]